Table 1. Autoantibodies targeting NY-ESO-1 and HER2 in cancer patients and healthy subjects.
| Diagnosis | Antigen | # Screened* | # Positive | % Positive | Titer** |
|---|---|---|---|---|---|
| Melanoma |
NY-ESO-1 |
80 |
9 |
11.5 |
350, 600, 1600, 32K, 50K, 50K, 64K, 150K, 250K |
| Healthy |
NY-ESO-1 |
33 |
0 |
0 |
n.a. |
| HER2+ breast cancer |
HER2 |
82 |
3 |
3.7 |
3K, 3K, 25K |
| HER2− breast cancer |
HER2 |
29 |
1 |
3.4 |
25K |
| Breast cancer |
HER2 |
59 |
4 |
6.8 |
600, 25K, 25K, 25K |
| Healthy | HER2 | 12 | 0 | 0 | n.a. |
*
Represents unique patients; **expressed as 1/dilution, at entry into the study. n.a., not available.